CELLECTIS (ALCLS.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALCLS - FR0010425595 - Common Stock
ALCLS.PA Key Statistics, Chart & Performance
The current stock price of ALCLS.PA is 4.435 EUR. In the past month the price increased by 43.76%. In the past year, price increased by 129.79%.
ALCLS.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 72.89 | 48.25B | ||
| ARGX.BR | ARGENX SE | 72.09 | 47.72B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.91B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.41B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.39B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.78B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.79B | ||
| 5CV.DE | CUREVAC NV | 5.45 | 1.07B | ||
| NANO.PA | NANOBIOTIX | N/A | 874.15M | ||
| PHIL.MI | PHILOGEN SPA | 19.87 | 662.29M | ||
| IVA.PA | INVENTIVA SA | N/A | 695.31M | ||
| 6IV.DE | INVENTIVA SA | N/A | 651.37M |
Related stock screener links
About ALCLS.PA
Company Profile
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 224 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
Company Info
CELLECTIS
8, rue de la Croix Jarry
Paris ILE-DE-FRANCE FR
Employees: 219
Phone: 33181691600
CELLECTIS / ALCLS.PA FAQ
Can you describe the business of CELLECTIS?
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 224 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
Can you provide the latest stock price for CELLECTIS?
The current stock price of ALCLS.PA is 4.435 EUR. The price decreased by -0.22% in the last trading session.
Does ALCLS stock pay dividends?
ALCLS.PA does not pay a dividend.
What is the ChartMill rating of CELLECTIS stock?
ALCLS.PA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of ALCLS stock?
CELLECTIS (ALCLS.PA) has a market capitalization of 444.94M EUR. This makes ALCLS.PA a Small Cap stock.
What is the next earnings date for ALCLS stock?
CELLECTIS (ALCLS.PA) will report earnings on 2026-03-11, after the market close.
Who owns CELLECTIS?
You can find the ownership structure of CELLECTIS (ALCLS.PA) on the Ownership tab.
ALCLS.PA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ALCLS.PA. When comparing the yearly performance of all stocks, ALCLS.PA is one of the better performing stocks in the market, outperforming 98.8% of all stocks.
ALCLS.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALCLS.PA. Both the profitability and financial health of ALCLS.PA have multiple concerns.
ALCLS.PA Financial Highlights
Over the last trailing twelve months ALCLS.PA reported a non-GAAP Earnings per Share(EPS) of -0.29. The EPS increased by 70.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.3% | ||
| ROE | -103.16% | ||
| Debt/Equity | 0.91 |
ALCLS.PA Forecast & Estimates
13 analysts have analysed ALCLS.PA and the average price target is 6.63 EUR. This implies a price increase of 49.49% is expected in the next year compared to the current price of 4.435.
For the next year, analysts expect an EPS growth of -213.93% and a revenue growth -3.47% for ALCLS.PA